Evidence map›Paper›PMID 36260109›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2023

The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy.

Carola Lütgendorf-Caucig, Maciej Pelak, Birgit Flechl, Petra Georg, Piero Fossati, Markus Stock, Tatjana Traub-Weidinger, Christine Marosi, Christine Haberler, Gloria Zechmeister-Machhart and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Annals of nuclear medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Carola Lütgendorf-CaucigMedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700, Wiener Neustadt, Austria.
Maciej PelakMedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700, Wiener Neustadt, Austria. maciej.pelak@medaustron.at.ORCID 0000-0001-9584-2996
Birgit FlechlMedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700, Wiener Neustadt, Austria.
Petra GeorgMedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700, Wiener Neustadt, Austria.
Piero FossatiMedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700, Wiener Neustadt, Austria.
Markus StockMedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700, Wiener Neustadt, Austria.
Tatjana Traub-WeidingerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Christine MarosiDivision of Palliative Care, Department of Internal Medicine 1, Medical University of Vienna, Vienna, Austria.
Christine HaberlerDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
Gloria Zechmeister-MachhartMedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700, Wiener Neustadt, Austria.
Lauritz HermsmeyerMedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700, Wiener Neustadt, Austria.
Eugen HugMedAustron Ion Therapy Center, Marie Curie-Straße 5, 2700, Wiener Neustadt, Austria.
Anton StaudenherzDepartment of Nuclear Medicine, University Clinic St. Poelten, St. Poelten, Austria.
MedAustron · ATMedical University of Vienna · ATKarl Landsteiner University of Health Sciences · ATUniversity of Applied Sciences St Pölten · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOverexpression of the somatostatin receptor (SSTR) has led to adoption of SSTR PET/CT for diagnosis and radiotherapy planning in meningioma, but data on SSTR expression during follow-up remain scarce. We investigated PET/CT quantifiers of SSTR tracers in WHO grade I meningioma following fractionated proton beam therapy (PBT) compared to standard response assessment with MRI.

methodsTwenty-two patients diagnosed with low-grade meningioma treated by PBT were included. Follow-up included clinical visits, MRI, and [

resultsMedian follow-up was 35.3 months (range: 6.4-47.9). Nineteen patients (86.4%, p = 0.0009) showed a decrease of SUVmax between baseline and first follow-up PET/CT (median: -24%, range: -53% to +89%) and in 81.8% of all cases, the SUVmax, SUVmean, and TLA at last follow-up were eventually lower than at baseline (p = 0.0043). Ambiguous trends without significance between the timepoints analyzed were observed for V

conclusionPET/CT in follow-up of irradiated meningioma showed an early trend towards decreased binding of SSTR-specific tracers following radiation and MRI demonstrated consistently stable or decreasing tumor volume. Translational research is needed to clarify the underlying biology of the subsequent increase in SSTR PET quantifiers.

Indexed as

Meningeal NeoplasmsMeningiomaOrganometallic CompoundsProton TherapyFollow-Up StudiesHumansMagnetic Resonance ImagingPositron-Emission TomographyPositron Emission Tomography Computed TomographyReceptors, SomatostatinOrganometallic CompoundsReceptors, SomatostatinFollow-upMagnetic resonance imagingRadiation therapySomatostatin receptorStandardized uptake value

Identifiers

PMID36260109
OpenAlexW4306793319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.